The diagnostic and prognostic value of LncRNA FAM3D-AS1 expression in nasopharyngeal carcinoma and its effect on tumor progression and cisplatin resistance.

BACKGROUND

The location of nasopharyngeal carcinoma (NPC) is relatively hidden. Most patients are diagnosed at the middle or late stage of the disease, having missed the best time for treatment.

AIM: To explore the clinical value of lncRNA FAM3D-AS1 and its effect on tumor progression and cisplatin resistance in nasopharyngeal cancer.

MATERIALS AND

METHODS

In this study, a total of 118 NPC patients and 50 healthy volunteers participated. RT-qPCR was analyzed to detect the lncRNA FAM3D-AS1 expression in NPC patients and cells. Receiver Operating Characteristic (ROC curves), Kaplan-Meier (K-M) survival curves and Cox regression analysis were performed to analyze the clinical value value of lncRNA FAM3D-AS1. Cell functional assays were employed to investigate the impact of lncRNA FAM3D-AS1 on biological malignant behavior of NPC and cisplatin resistance.

RESULTS

In NPC patients' serum and cell lines, the expression of lncRNA FAM3D-AS1 was upregulated. ROC curves with Area Under the Curve (AUC) = 0.920, 95%CI = 0.874-0.965 could be used to distinguish the healthy group from the NPC group. K-M survival curves revealed that NPC patients with high expression of lncRNA FAM3D-AS1 had poor prognosis. Cox regression analysis suggested that lncRNA FAM3D-AS1 was an independent prognostic marker for NPC. Knockdown of lncRNA FAM3D-AS1 expression prohibited NPC cell proliferation, migration, invasion, and cisplatin resistance, but promoted apoptosis.

CONCLUSION

LncRNA FAM3D-AS1 can be used as a biomarker to diagnose and prognosticate NPC. LncRNA FAM3D-AS1 affects tumor progression and cisplatin resistance in NPC.